Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Omeros Corporation - Common Stock (NQ:OMER)

9.690 +0.470 (+5.10%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Omeros Corporation - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Omeros Corporation Reports Second Quarter 2022 Financial Results
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2022
From Omeros Corporation
Via Business Wire
News headline image
FDA Grants Orphan Drug Designation to Omeros’ MASP-3 Inhibitor OMS906 for Treatment of Paroxysmal Nocturnal Hemoglobinuria
From Omeros Corporation
Via Business Wire
News headline image
Omeros Announces Webcast Details for Annual Meeting of Shareholders
From Omeros Corporation
Via Business Wire
Small-Cap Psychedelic Play Vying for Future Leadership in Addiction Treatment (AXSM, AWKNF, BICX, OPNT, ALKS, PFE, AMPH, OMER)
Via AB Newswire
News headline image
Omeros Corporation Reports First Quarter 2022 Financial Results
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation to Announce First Quarter Financial Results on May 10, 2022
From Omeros Corporation
Via Business Wire
News headline image
Omeros Announces Journal of Clinical Oncology Publication Detailing Pivotal Trial Results for Narsoplimab in HSCT-TMA
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 1, 2022
From Omeros Corporation
Via Business Wire
News headline image
Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA
From Omeros Corporation
Via Business Wire
News headline image
Omeros Completes Sale of OMIDRIA® Franchise to Rayner Surgical
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation (NASDAQ:OMER) Investor Notice: Investigation over Potential Wrongdoing ↗
San Diego, CA -- (SBWIRE) -- 12/14/2021 -- Certain directors of Omeros Corporation are under investigation over potential breaches of fiduciary duties. 
Via SBWire
News headline image
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation and Encourages Investors with Losses to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Omeros Announces Agreement to Sell OMIDRIA® Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation Reports Third Quarter 2021 Financial Results
From Omeros Corporation
Via Business Wire
News headline image
Omeros Announces Results From Nearly Three-Year Follow-up of Patients in Phase 2 IgA Nephropathy Trial
From Omeros Corporation
Via Business Wire
News headline image
Omeros’ Narsoplimab Stabilized Kidney Function and Reduced Urinary Complement Proteins in a Patient with IgA Vasculitis
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2021
From Omeros Corporation
Via Business Wire
News headline image
NASDAQ:OMER Investor Notice: Investigation over Possible Securities Laws Violations by Omeros Corporation ↗
San Diego, CA -- (SBWIRE) -- 10/22/2021 -- An investigation was announced concerning potential securities laws violations by Omeros Corporation in connection with certain financial statements. 
Via SBWire
News headline image
Omeros Receives Complete Response Letter from FDA for Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA
From Omeros Corporation
Via Business Wire
News headline image
OMEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating Omeros Corporation on Behalf of Omeros Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
News headline image
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Omeros Corporation (OMER) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Omeros Corporation (OMER) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Omeros Corporation and Encourages Investors With Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
OMER INVESTOR ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Omeros Corporation Investors with Losses to Inquire About Class Action Investigation – OMER
From Rosen Law Firm
Via Business Wire
News headline image
Omeros Provides Regulatory Update on Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation Reports Second Quarter 2021 Financial Results
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2021
From Omeros Corporation
Via Business Wire
News headline image
Omeros’ Narsoplimab Pivotal Trial Data Shared in Oral Presentation at 2021 Annual Congress of the European Hematology Association
From Omeros Corporation
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.